Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Helix, a leading population genomics company and provider of precision medicine genomics solutions, today announced a groundbreaking multi-year agreement with ...

Recursion is a leading, clinical-stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse ...

SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

For years, drug developers that apply artificial intelligence (AI) have touted the benefits of the technology—the prospect of speedier development of new treatments at lower cost, thus reducing the ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Biotech Recursion announced a definitive merger agreement with drug design and development company Exscientia on Thursday morning. The combined company, which is expected to yield annual synergies of ...